Myriad Genetics to acquire Rules-Based Medicine

Diagnostic company Myriad Genetics Inc. (NASDAQ:MYGN) said late Wednesday that it will acquire Rules-Based Medicine Inc. (Austin, Texas) for $80 million in cash. RBM, which provides biomarker testing based on its Multi-Analyte Profiling (MAP) technology, had about $25 million in revenues last year. Jefferies advised RBM on the deal, which is expected to close by the end of May. ...